Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.45 EUR | +1.21% | -3.91% | +10.58% |
Apr. 17 | GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix | MT |
Apr. 17 | GSK: positive clinical results for gonorrhea | CF |
Sales 2024 * | 31.46B 38.92B 36.52B | Sales 2025 * | 33.33B 41.23B 38.69B | Capitalization | 65.34B 80.82B 75.84B |
---|---|---|---|---|---|
Net income 2024 * | 5.63B 6.96B 6.53B | Net income 2025 * | 6.37B 7.88B 7.39B | EV / Sales 2024 * | 2.46 x |
Net Debt 2024 * | 12.16B 15.04B 14.12B | Net Debt 2025 * | 8.93B 11.04B 10.36B | EV / Sales 2025 * | 2.23 x |
P/E ratio 2024 * |
11.6
x | P/E ratio 2025 * |
10.3
x | Employees | 70,212 |
Yield 2024 * |
3.81% | Yield 2025 * |
4.07% | Free-Float | 92.58% |
Latest transcript on GSK plc
1 day | +1.21% | ||
1 week | -3.91% | ||
Current month | -7.03% | ||
1 month | -4.30% | ||
3 months | +2.19% | ||
6 months | +11.82% | ||
Current year | +10.58% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 18.45 | +1.21% | 271 |
24-04-18 | 18.23 | -0.63% | 276 |
24-04-17 | 18.34 | -1.37% | 2,670 |
24-04-16 | 18.6 | -4.71% | 0 |
24-04-15 | 19.52 | +1.67% | 113 |
Delayed Quote Deutsche Boerse AG, April 19, 2024 at 03:49 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- GSK Stock
- GS71 Stock